Carboxamide compounds and their use as calpain inhibitors

Details Carboxamide compounds and their use as calpain inhibitors Carboxamide compounds and their use as calpain inhibitors

2008-02-22

2010-06-01

Padmanabhan, Sreeni (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S061000, C546S275400

Reexamination Certificate

active

07728012

ABSTRACT:
The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.The carboxamide compounds are compounds of the general formula Iin which R1, R2, R3a, R3b, W, Y and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula I-A.a′ and I-A.a″in which m, E, R1, R3a, R3b, R2, Ry, Rwand Rw6* have the meanings mentioned in the claims, n is 0, 1 or 2, the tautomers thereof and the pharmaceutically suitable salts thereof.

REFERENCES:
patent: 6482832 (2002-11-01), Lubisch et al.
patent: 6562827 (2003-05-01), Lubisch et al.
patent: 6630493 (2003-10-01), Lubisch et al.
patent: WO 98/16512 (1998-04-01), None
patent: WO 98/25899 (1998-06-01), None
patent: WO 99/17775 (1999-04-01), None
patent: WO 99/54293 (1999-10-01), None
patent: WO 99/54294 (1999-10-01), None
patent: WO 99/54304 (1999-10-01), None
patent: WO 99/54305 (1999-10-01), None
patent: WO 99/54310 (1999-10-01), None
patent: WO 99/54320 (1999-10-01), None
patent: WO 99/61423 (1999-12-01), None
patent: WO 03/080182 (2003-10-01), None
Neffe et al., Current Opinion in Drug Discovery & Development “Developments in the Design and Synthesis of Calpain Inhibitors”, 2005 8(6) pp. 684-700, XP0009072341.
Barrett et al., Life Sciences, “Effect of Substrate on Ca2+ -Concentration Required for Activity of the Ca2+ -Dependent Proteinases, u- and m-Calpain”, vol. 48, pp. 1659-1669, 1991.
Bartus et al., Neurological Research, “Calpain as a Novel Target for Treating Acute Neurodegenerative Disorders”, 1995, vol. 17, pp. 249-258.
Carragher, Current Pharmaceutical Design, “Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States”, 2006, 12, pp. 615-638.
Cuzzocrea et al., American Journal of Pathology, “Calpain Inhibitor I Reduces the Development of Acute and Chronic Inflammation”, vol. 157, No. 6, Dec. 2000, pp. 2065-2079.
Edelstein et al., Proc. Nat. Acad. Sci. USA, “The Role of Cysteine Proteases in Hypoxia-Induced Rat Renal Proximal Tubular Injury”, vol. 92, Aug. 1995, pp. 7662-7666.
Fehrentz et al., Centre CNRS-INSERM de Pharmacologie-Endocrinologie, Rue de la Cardonille, B.P. 5055, F-34033 Montpellier Cedex, “An Efficient Synthesis of Optically Active a-(t-Butoxycarbonylamino)-aldehydes from a-Amino Acids”, pp. 676-678, 1983.
Higaki et al., Neuron “Inhibition of B-Amylois Fomation Identifies Proteolytic Precursors and Subcellular Site of Catabolism”, vol. 14, Mar. 1995, pp. 651-659.
Higuchi et al., The Journal of Biological Chemistry, “Distinct Mechanistic Roles of Calpain and Caspase Activation in Neurodegeneration as Revealed in Mice Overexpressing Their Specific Inhibitors”, 2005, vol. 280, No. 15, pp. 15229-15237.
Kunz et al., International Association for the Study of Pin, “The Calpain Inhibitor MDL 28170 Prevents Inflammation-Induced Neurofilament Light Chain Breakdown in the Spinal Cord and Reduces Thermal Hyperalgesis”, 2004, 110, pp. 409-418.
Hassen et al., Journal of Neuroimmunology, “A Novel Calpain Inhibitor for the Treatment of Acute Experimental Autoimmune Encephalomyelitis”, 2006, 180, pp. 135-146.
Monaco, Bentham Science Publishers, “Recent Evidence Regarding a Role for Cdk5 Dysregulation in Alzheimer's Disease”, 2004.
O'Donnell, The Journal of Neuroscience, “Human Innumodeficiency Virus (HIV)-Induced Neurotoxicity: Roles for the NMDA Receptor Subtypes 2A and 2B and the Calcium-Activated Protease Calpain by a CSF-Derived HIV-1 Strain”, Jan. 18, 2006, 26(3), pp. 981-990.
Park et al., The Journal of Neuroscience, “The Generation of a 17 kDa Neurotoxic Fragment: An Alternative Mechanism by Which Tau Mediates B-Amyloid-Induced Neurodegeneration”, Jun. 1, 2005, 25(22), pp. 5365-5375.
Patrick et al., Nature, “Conversion of p35 to p25 Deregulates Cdk5 Activity and Promotes Neurodegeneration”, Dec. 9, 1999, vol. 402, pp. 615-622.
Saatman et al., Proc. Natl. Acad. Sci. USA, “Calpain Inhibitor AK295 Attenuates Motor and Cognitive Deficits Following Experimental Brain Injury in the Rat”, Apr. 1996, vol. 93, pp. 3428-3433.
Saez et al., Drug Discovery Today, “The Therapeutic Potential of the Calpain Family: New Aspects”, Oct. 2006, vol. 11, Nos. 19/20, pp. 917-923.
Hong et al., Stroke, “Neuroprotection With a Calpain Inhibitor in a Model fo Focal Cerebral Ischemia”, Mar. 1994, vol. 25, No. 3, pp. 663-669.
Shiba et al., International Journal of Oncology, “Mechanism of Growth Inhibition of MCF-7 by a Cell Permeable Calpin Inhibitor”, 1994.
Suzuki et al., Biol. Chem. Hoppe-Seyler “Calpain: Novel Family Members, Activation, and Physiological Funcation”, Sep. 1995, vol. 376, pp. 523-529.
Teranishi et al., Biochemical and Biophysical Research Communications, “Calpain is involved in the HIV Replication from the Latently Infected OM10.0 Cells”, 2003, 303, pp. 940-946.
Wang et al., Brain, “Calpain Inhibition Protects Against Taxol-induced Sensory Neuropathy”, 2004, 127, pp. 671-679.
Yuen et al., Drugs of the Future, “Calpain Inhibitors: Novel Neuroprotectants and Potential Anticataract Agents”, 1998, 23(7), pp. 741-749.
Wang et al., TIPS, “Calpain Inhibition: an Overview of its Therapeutic Potential”, Nov. 1994, vol. 15, pp. 412-419.
Watanabe et al., Cytokine, “Selective Release of a Processed Form of Interleukin 1a”, Nov. 1994, vol. 6, No. 6, pp. 597-601.
Yoshida et al., Japanese Circulation Journal, “Calpain is Implicated in Rat Myocardial Injury After Ischemia or Reperfusion”, Jan. 1995, vol. 59, pp. 40-48.

Affiliated with

Also associated with

Rating

Carboxamide compounds and their use as calpain inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Carboxamide compounds and their use as calpain inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carboxamide compounds and their use as calpain inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4187285